Increasing high-density lipoprotein as a therapeutic target in atherothrombotic disease

Area of Science:

• Cardiovascular Medicine
• Lipid Metabolism
• Atherosclerosis Research

Background:

• Atherothrombosis and its complications represent a major global health burden.
• Elevated LDL cholesterol and low HDL cholesterol are key risk factors for atherothrombosis.
• While statins effectively reduce LDL, many patients still experience cardiovascular events.

Purpose of the Study:

• To review the biological rationale for increasing HDL cholesterol levels.
• To discuss the potential benefits of HDL-targeting therapies in cardiovascular disease prevention.
• To explore novel treatment approaches for high-risk patients.

Main Methods:

• Review of recent animal studies and clinical trials on HDL-raising therapies.
• Analysis of the mechanisms by which HDL influences atheromatous plaque.
• Discussion of intravenous HDL preparations and their clinical implications.

Main Results:

• Increasing HDL levels may provide benefits beyond LDL reduction with statins.
• Intravenous HDL preparations show potential for plaque regression and stabilization.
• Earlier trials had limitations due to non-standardized statin treatments.

Conclusions:

• Targeting HDL represents a promising novel therapeutic strategy for atherothrombosis.
• HDL-infusion therapies could offer additional benefits for high-risk cardiovascular patients.
• Further research into HDL-based treatments is warranted for comprehensive atherothrombosis management.